knowledge -WSS

knowledge

author：focus 2025-08-28 03:34:28 - browse：57

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

explore

WSS

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Study on Amgen’s bispecific immunotherapy produces positive data

A letter from the executive editor: The 2023 STATUS List

CZI to create biohub to build anti

UnitedHealth, Optum discontinue NaviHealth name

Wikipedia

knowledge

entertainment

The high cost of giving birth even with insurance

AstraZeneca lung cancer study comes in below expectations

Affirmative action in medical school literally saved lives

Hubble vs. James Webb telescope images: See the difference

Medicare proposal to cover medical devices draws a mixed reaction

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

The cancer drug shortage isn’t new — and neither are the solutions

STAT Summit: The economic case for universal basic health care

How one medical school became remarkably diverse

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

leisure time

Use doctors trained outside the U.S. to ease the physician shortage

STAT Summit: The economic case for universal basic health care

A letter from the executive editor: The 2023 STATUS List

Use doctors trained outside the U.S. to ease the physician shortage

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Use doctors trained outside the U.S. to ease the physician shortage

focus

explore

entertainment

explore